AXSM

137.75

6.70% 8.65

Handel nachbörslich: 138.95 1.20 +0.87%

Axsome Therapeutics Inc (AXSM)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt AXSM? Forum Prognose

Schlusskurs vom Vortag:

$129.10

Offen:

$130.04

24-Stunden-Volumen:

1.48M

Relative Volume:

1.74

Marktkapitalisierung:

$6.54B

Einnahmen:

$338.46M

Nettoeinkommen (Verlust:

$-310.96M

KGV:

-21.09

EPS:

-6.53

Netto-Cashflow:

$-132.82M

1W Leistung:

+5.03%

1M Leistung:

+43.22%

6M Leistung:

+56.69%

1J Leistung:

+67.76%

1-Tages-Spanne:

$128.38

$139.13

1-Wochen-Bereich:

$124.03

$139.13

52-Wochen-Spanne:

$64.11

$139.13

Axsome Therapeutics Inc Stock (AXSM) Company Profile

Firmenname

Axsome Therapeutics Inc

Sektor

Healthcare (1169)

Branche

Biotechnology (678)

Telefon

(212) 332-3241

Adresse

ONE WORLD TRADE CENTER, 22ND FLOOR, NEW YORK

Mitarbeiter

569

Twitter

Nächster Verdiensttermin

2025-02-18

Neueste SEC-Einreichungen

AXSM's Discussions on Twitter

Vergleichen Sie AXSM mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
AXSM Axsome Therapeutics Inc	137.75	6.54B	338.46M	-310.96M	-132.82M	-6.53
VRTX Vertex Pharmaceuticals Inc	484.24	124.35B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	700.33	76.56B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	644.48	39.16B	1.86B	-40.29M	-1.28B	-0.85
ALNY Alnylam Pharmaceuticals Inc	250.59	32.44B	2.25B	-278.16M	-42.59M	-2.17
BNTX Biontech Se Adr	120.01	28.77B	3.30B	-501.07M	1.03B	-2.1146

Axsome Therapeutics Inc Stock (AXSM) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-02-11	Eingeleitet	Deutsche Bank	Buy
2024-12-31	Bestätigt	Mizuho	Outperform
2024-09-03	Eingeleitet	Wells Fargo	Overweight
2024-08-06	Hochstufung	BofA Securities	Neutral → Buy
2024-07-22	Eingeleitet	Needham	Buy
2024-04-29	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2024-03-19	Eingeleitet	Robert W. Baird	Outperform
2024-02-06	Eingeleitet	UBS	Buy
2024-01-25	Eingeleitet	RBC Capital Mkts	Outperform
2023-12-13	Eingeleitet	Citigroup	Buy
2023-08-08	Hochstufung	BofA Securities	Underperform → Neutral
2023-01-05	Eingeleitet	Piper Sandler	Neutral
2022-11-01	Eingeleitet	Loop Capital	Buy
2022-09-07	Fortgesetzt	Mizuho	Buy
2021-08-10	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2021-06-10	Eingeleitet	Berenberg	Buy
2021-01-08	Eingeleitet	Jefferies	Buy
2020-12-16	Eingeleitet	Mizuho	Buy
2020-09-29	Eingeleitet	BofA Securities	Underperform
2020-09-10	Eingeleitet	Morgan Stanley	Overweight
2020-04-28	Bestätigt	H.C. Wainwright	Buy
2020-04-14	Eingeleitet	Cowen	Outperform
2019-12-30	Bestätigt	H.C. Wainwright	Buy
2019-12-17	Bestätigt	H.C. Wainwright	Buy
2019-12-16	Bestätigt	Guggenheim	Buy
2019-10-16	Eingeleitet	Guggenheim	Buy
2019-09-18	Eingeleitet	William Blair	Outperform
2019-05-28	Eingeleitet	SunTrust	Buy
2019-05-23	Bestätigt	H.C. Wainwright	Buy
2019-04-08	Eingeleitet	SVB Leerink	Outperform
2019-03-15	Bestätigt	H.C. Wainwright	Buy
2016-10-03	Fortgesetzt	Brean Capital	Buy
2015-12-15	Eingeleitet	Cantor Fitzgerald	Buy
2015-12-14	Eingeleitet	Ladenburg Thalmann	Buy

Alle ansehen

Axsome Therapeutics Inc Aktie (AXSM) Neueste Nachrichten

11:42 AM

Axsome Therapeutics (NASDAQ:AXSM) Hits New 52-Week High on Analyst Upgrade - MarketBeat

11:42 AM

09:10 AM

Axsome Therapeutics stock soars to all-time high of $134.2 By Investing.com - Investing.com Nigeria

Feb 21, 2025

Axsome Therapeutics (NASDAQ:AXSM) Issues Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat

Feb 21, 2025

Axsome Therapeutics stock soars to all-time high of $134.2 - Investing.com India

Feb 21, 2025

Axsome Therapeutics (NASDAQ:AXSM) Releases Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat

Feb 21, 2025

Astrazeneca, Vertex, Axsome secure US FDA approvals in January - BioWorld Online

Feb 21, 2025

Axsome Therapeutics targets multiple NDA submissions and pipeline advancements through 2025 - MSN

Feb 21, 2025

Mizuho maintains Axsome Outperform rating, $195 target - Investing.com

Feb 21, 2025

Axsome Therapeutics (NASDAQ:AXSM) Price Target Raised to $200.00 at HC Wainwright - MarketBeat

Feb 21, 2025

FY2028 Earnings Estimate for AXSM Issued By Leerink Partnrs - MarketBeat

Feb 21, 2025

Axsome Therapeutics’ Earnings Call: Growth Amid Challenges - TipRanks

Feb 21, 2025

Strategic Financial Concepts LLC Takes Position in Axsome Therapeutics, Inc. (NASDAQ:AXSM) - MarketBeat

Feb 21, 2025

Feb 20, 2025

Telomir Pharmaceuticals Seeks To Tap Multi-Billion-Dollar Market With Breakthrough In Silver Ion Stabilization For Antibacterial Treatment, Tissue Regeneration - AOL

Feb 20, 2025

Axsome Therapeutics Stock Slips On Q4 Profit Miss, But Retail Takes It In Stride - MSN

Feb 20, 2025

Axsome Therapeutics (NASDAQ:AXSM) Receives Outperform Rating from William Blair - MarketBeat

Feb 20, 2025

Truist Financial Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat

Feb 20, 2025

Cantor Fitzgerald Reaffirms Overweight Rating for Axsome Therapeutics (NASDAQ:AXSM) - MarketBeat

Feb 20, 2025

Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering (NASDAQ:AXSM) - Seeking Alpha

Feb 20, 2025

Needham & Company LLC Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock - MarketBeat

Feb 20, 2025

Axsome Therapeutics Revenue Surges 66% - MSN

Feb 20, 2025